Dana-Farber Cancer Institute

1026 Words5 Pages
TEAM A Ataa Nyamekye Michael Weinreich Case: The Dana-Farber Cancer Institute The key decision maker in this case is Dr. Stephen Sallan, Senior Oncologist and Physician-in-Chief of the Dana-Farber Cancer Institute. Key Facts: The Dana-Farber Cancer Institute is among one of the best cancer centers for both oncological research and clinical care in the United States. Founded in 1947, the institute was originally focused on treated cancers in children. By placing top laboratory researchers in the same physical building as expert clinical physicians, the hope was that “the problems of the patients would be brought up to the labs and ideas from the labs would go down to the patients.” The Dana-Farber Cancer Institute was placed within close proximity to other well-known hospitals and research centers such as the Brigham and Women’s Hospital, Beth Israel-Deaconess Medical Center, Boston Children’s Hospital, and Harvard Medical School. As such, patients who walked into the Cancer Institute knew by the very reputation and geographical ties to other research institutions, that they would be subject of various research protocols and the newest and cutting edge treatment protocols. The institute’s extremely intelligent staff allowed for such complicated protocols to be initiated under close guidance. While other hospitals may have struggled to keep up with the rapidly changing treatment plans, the staff at Dana-Farber worked their hardest to ensure their patients were receiving the best and safest possible care. Among one of the most widely used oncologic treatments is that of chemotherapy. Chemotherapy exploits the uncontrolled growth characteristics of cancer cells to target them for death. Chemotherapeutic drugs act against both extremely rapidly replicating cancer cells as well as other normal cells in the body that are also replicating. Cells of the
Open Document